Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
August 07, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader...
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Oncocyte Announces August Investor Conferences Participation
August 05, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte Announces August Investor Conferences Participation
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
August 01, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
August 01, 2024 09:00 ET
|
Outpace Bio
Seattle, WA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- – Financing syndicate led by RA Capital Management with significant support from a world-class group of existing and new healthcare investors –...
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
August 01, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 31, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies
July 31, 2024 07:00 ET
|
Umoja Biopharma, Inc.
- UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor (CAR)-T cell therapy to be evaluated in humans in the hematology setting - - First patient expected to be dosed by...
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
July 31, 2024 07:00 ET
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Avance Clinical Announces Senior Appointment to North American Operations
July 31, 2024 02:45 ET
|
Avance Clinical
ADELAIDE, Australia and WAKE FOREST, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, an award-winning, mid-sized full-service global Contract Research Organization (CRO) for biotech...